Bhawana Adhikari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bhawana Adhikari has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anupriya Adhikari
Department of Chemistry Graphic Era Hill University Dehradun Uttrakhand India
1 shared publication - Dayun Yan
Department of Mechanical and Aerospace Engineering, George Washington University, Washington, DC 20052, USA
1 shared publication - Jonathan H. Sherman
Department of Neurosurgery, West Virginia University, Martinsburg, West Virginia, USA
1 shared publication - Manish Adhikari
Plasma Bioscience Research Center, Applied Plasma Medicine Center, Department of Electrical and Biological Physics, Kwangwoon University, Seoul 01897, Korea
1 shared publication - Michael Keidar
Department of Mechanical and Aerospace Engineering, the George Washington University, Washington, DC 20052, USA
1 shared publication - Vikas Soni
Micropropulsion and Nanotechnology Laboratory (MPNL), School of Engineering and Applied Science, George Washington University, 800 22nd St. NW, Suite 3100, Washington, DC 20052, USA
1 shared publication
Latest Publications
- 17 June 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (19) , 2195-2206
Cold Atmospheric Plasma as a Novel Therapeutic Tool for the Treatment of Brain Cancer
Background: Studies from the past few years revealed the importance of Cold Atmospheric Plasma (CAP) on various kinds of diseases, including brain cancers or glioblastoma (GBM), and hence coined a new term ‘Plasma Medicine’ in the modern world for promising therapeutic approaches. Here, we focus on the efficacy of CAP and its liquid derivatives on direct interactions or with specific nanoparticles to show pivotal roles in brain cancer treatment. Method: In the present review study, the authors studied several articles over the past decades published on the types of CAP and its effects on different brain cancers and therapy. Results: A growing body of evidence indicates that CAP and its derivatives like Plasma Activated Media/ Water (PAM/PAW) are introduced in different kinds of GBM. Recent studies proposed that CAP plays a remarkable role in GBM treatment. To increase the efficacy of CAP, various nanoparticles of different origins got specific attention in recent times. In this review, different strategies to treat brain cancers, including nanoparticles, are discussed as enhancers of CAP induced targeted nanotherapeutic approach. Conclusion: CAP treatment and its synergistic effects with different nanoparticles hold great promise for clinical applications in early diagnosis and treatment of GBM treatment. However, results obtained from previous studies were still in the preliminary phase, and there must be a concern over the use of optimal methods for a dosage of CAP and nanoparticles for complete cure of GBM.
- 17 June 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (19) , 2195-2206
Cold Atmospheric Plasma as a Novel Therapeutic Tool for the Treatment of Brain Cancer
Background: Studies from the past few years revealed the importance of Cold Atmospheric Plasma (CAP) on various kinds of diseases, including brain cancers or glioblastoma (GBM), and hence coined a new term ‘Plasma Medicine’ in the modern world for promising therapeutic approaches. Here, we focus on the efficacy of CAP and its liquid derivatives on direct interactions or with specific nanoparticles to show pivotal roles in brain cancer treatment. Method: In the present review study, the authors studied several articles over the past decades published on the types of CAP and its effects on different brain cancers and therapy. Results: A growing body of evidence indicates that CAP and its derivatives like Plasma Activated Media/ Water (PAM/PAW) are introduced in different kinds of GBM. Recent studies proposed that CAP plays a remarkable role in GBM treatment. To increase the efficacy of CAP, various nanoparticles of different origins got specific attention in recent times. In this review, different strategies to treat brain cancers, including nanoparticles, are discussed as enhancers of CAP induced targeted nanotherapeutic approach. Conclusion: CAP treatment and its synergistic effects with different nanoparticles hold great promise for clinical applications in early diagnosis and treatment of GBM treatment. However, results obtained from previous studies were still in the preliminary phase, and there must be a concern over the use of optimal methods for a dosage of CAP and nanoparticles for complete cure of GBM.